BRIEF-Bristol Myers Squibb Says Sotyktu Well-Tolerated Compared To Placebo And Apremilast

Reuters
08 Mar
BRIEF-Bristol Myers Squibb Says Sotyktu Well-Tolerated Compared To Placebo And Apremilast

March 8 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB PRESENTS LATE-BREAKING DATA FROM PHASE 3 POETYK PSA-2 TRIAL DEMONSTRATING SUPERIORITY OF SOTYKTU (DEUCRAVACITINIB) COMPARED WITH PLACEBO IN ADULTS WITH PSORIATIC ARTHRITIS

  • BRISTOL-MYERS SQUIBB CO - SOTYKTU WELL-TOLERATED COMPARED TO PLACEBO AND APREMILAST

Source text: ID:nBw5yNC9Ka

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10